Skip to main content
. 2013 Jan 30;8(1):27–33. doi: 10.1007/s11523-013-0258-9

Fig. 1.

Fig. 1

Progression-free survival in IPASS. a Kaplan–Meier curves of PFS for Asian patients treated with gefitinib or carboplatin plus paclitaxel who had pulmonary adenocarcinoma and who were light or nonsmokers. b and c show PFS for patients with or without EGFR mutations treated with gefitinib or carboplatin plus paclitaxel, respectively, in subset analyses. [14]